Press ReleasesVyripharm Biopharmaceuticals and Regis Technologies, Inc. Have Signed Off on a Master Drug Program Agreement for Expediting cGMP Manufacture of Our Antiviral Agents for Diagnostic Evaluation of COVID-19.

Vyripharm Biopharmaceuticals and Regis Technologies, Inc. Have Signed Off on a Master Drug Program Agreement for Expediting cGMP Manufacture of Our Antiviral Agents for Diagnostic Evaluation of COVID-19.

HOUSTON–(BUSINESS WIRE)–Vyripharm Biopharmaceuticals, a subsidiary of Vyripharm Enterprises, LLC, a privately held company located in the Texas Medical Center in Houston, Texas, announced today that it has signed off on a Master Drug Program Agreement with Regis Technologies, Inc. Regis is a privately held contract development manufacturing organization (CDMO) in Morton Grove, Illinois. The agreement allows Vyripharm to further develop its antiviral diagnostic agents to first-in-humans studies of viral infections such as SARS, MERS and COVID-19.

With the ongoing COVID-19 pandemic, the pharmaceutical and medical industry is working around the clock to develop treatments, vaccines and accurate in-vitro testing applications of the viral infection. While two therapeutic agents, remdesivir and plaquenil, biologically have demonstrated mild disease control in very severe symptomatic patients; there still remains a need for developing treatment for the larger patient population as well as a vaccine to ultimately control widespread transmission. Furthermore, an overlooked need is the ability to accurately diagnose and evaluate the severity of the disease. Like many diseases, there appears to be varying COVID-19 patient profiles, where predictability of symptomatic response or clinical indications based on profiles have yet to be determined. Vyripharm seeks to apply its platform technology to address an in-vivo human diagnostic antiviral imaging agents for the evaluation and treatment outcomes.

Thus, the emergence of the COVID-19 pandemic has created the critical need for new strategies for diagnosis, evaluation, treatment and treatment outcomes; Vyripharm has redirected efforts with its platform technology towards diagnostic intervention of viral infections. Vyripharm’s drug platform technology includes an anti-viral (VYR-2020) and a CB1 antagonist (VYR-206) that integrates nuclear medicine imaging and diagnostic applications. Vyripharm’s technology has the potential to provide early onset diagnosis; infection monitoring; severity evaluation and ultimately treatment outcomes of COVID-19.

Vyripharm recognizing the need for expediting our efforts and having a Master Drug Program Agreement with Regis Technologies, Inc., a leading company in developing drug candidates to market made just good sense to do so at this present time in reference to the pandemic. Regis has agreed to scale up our drug candidates, VYR-2020 and VYR-206, for process research, preclinical (animal studies) and clinical (first-in-humans). More importantly, Regis is a company that has worked with pharmaceutical and biotechnology companies for over 60 years to develop active pharmaceutical ingredients (APIs) and high value intermediates under GMP manufacture. Again, with a Drug Manufacture Agreement in place with Regis, Vyripharm feels confident that we will advance our efforts in a timely and cost-effective manner.

Drag View

VYRIPHARM IS COMMITTED TO:

Helping People Live Better Lives

Quality Assurance and Quality Control is Vyripharm’s focus for enhancing public safety, public health and public awareness.